Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 12Gene Expression Profiling 7Flow Cytometry 7Gemtuzumab 6Polymerase Chain Reaction 5Idarubicin 5Daunorubicin 5Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Microarray Analysis 3Immunologic Techniques 3DNA Methylation 3sargramostim 2Reverse Transcriptase Polymerase Chain Reaction 2Observation 2Mitoxantrone 2In Situ Hybridization, Fluorescence 2Filgrastim 2Etoposide 2Cyclosporine 2Clofarabine 2Caspofungin 2Blotting, Western 2zosuquidar trihydrochloride 1lestaurtinib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Whole Genome Sequencing 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Congenital Abnormalities × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡